Study of outcomes in primary membranous nephropathy
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial looks at how people with primary membranous nephropathy (a kidney disease that causes swelling and protein in urine) do over time with their current treatment. It helps doctors understand which treatments work best, especially for those with severe protein loss.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with primary membranous nephropathy (a kidney condition that causes protein to leak into urine)
- You have nephrotic syndrome (protein in your urine above 3.5 grams per day)
- You are able to make your own medical decisions
- You are not unable to take rituximab or similar antibody treatments
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at blood and tissue samples from people with membranous nephropathy, a kidney disease, to find biological markers that predict whether rituximab, a treatment, will work. The goal is to understand why some patients do not respond, which could lead to better personalized treatment.
This trial tests a combination of two medications, rituximab and cyclosporine, for people with primary membranous nephropathy, a kidney disease that causes protein in the urine. The goal is to see if this combination can reduce protein loss and improve kidney function, potentially preserving kidney health.
This study is testing a tool that uses patient information to predict how quickly primary membranous nephropathy (a kidney disease) may progress. If you join, your data may help doctors better understand and plan treatment for this condition.
This study tests whether adding belimumab to rituximab helps people with primary membranous nephropathy (a kidney disease) that has the right blood test marker and specific protein levels. The goal is to improve kidney outcomes and reduce disease activity while keeping treatment safe.
This study looks at how well a treatment works for people with primary membranous nephropathy (PMN), a kidney condition. It is meant for patients who still have high protein in their urine despite taking standard blood pressure medicines.
This study tests a new medicine called JMT601 for people with primary membranous nephropathy (a kidney condition causing protein leakage). The goal is to see if the medicine can reduce protein in the urine while being safe.
Hear when a new Membranous Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.